Pilot Study to Assess the Efficacy of and Tolerance to a QUadruple Therapy to Treat HIV-HCV Coinfected Patients Previously Null Responders

Inclusion Criteria: * Adult ≥18 years with confirmed HIV-1 or 2 infection * Infection with HCV genotype 1 or 4 only, confirmed and with detectable HCV-RNA ≥ 1000 IU/mL at screening. * Null responders to a previous treatment with Peginterferon and Ribavirin, defined by a fall of less than 2 log10 IU/ml HCV-RNA from baseline to week 12. * Stable antiretroviral treatment for \> 1 month at screening containing any of the following drugs: Raltegravir, Enfuvirtide, Tenofovir-Emtricitabine, Abacavir-Lamivudine. * CD4 \> 200 /mm3 and \> 15% at screening * HIV-RNA \< 400 copies/mL from ≥ 3 months at screening * Any liver fibrosis stage, * with the assessment of the presence or not of cirrhosis at screening: * previous liver biopsy exhibiting cirrhosis lesions (METAVIR F4), and/or * significant liver biopsy (cumulative length ≥ 15 mm and ≥ 6 portal spaces), within 18 months and after the end of last HCV treatment, and/or * significant and reliable liver stiffness assessment (Fibroscan®) within 6 months (at least 10 measures with IQR less then 25% of the mean value and a success rate of at least 80%) * cirrhosis being defined as a METAVIR score F4 on liver biopsy and/or liver elastometry ≥ 15 kPa * the proportion of patients with cirrhosis (METAVIR F4) is limited to 50% of all patients. * Body weight ≥ 40 kg and ≤125 kg * Male patients, female patients with child-bearing potential and their heterosexual partners must use adequate contraception from 1 month before initiation of treatment to 7 months following the end of treatment for men and to 4 months following the end of treatment for women. * Informed and signed consent * For participating patients, informed and signed consent for the pharmacokinetic sub-study * Patients affiliated to the National Health Insurance or covered by Universal Medical Coverage * For the first 12 patients included (who will participate to the pharmacological substudy): stable antiretroviral treatment for \> 1 month at screening, with Raltegravir+ Emtricitabine+ Tenofovir Exclusion Criteria: * CHILD B and C cirrhosis, past history of decompensated cirrhosis. Patients with CHILD A cirrhosis must demonstrate the absence of significant oesophageal varices (Stages 2-3) on an upper gastrointestinal endoscopy ≤ 12 months * Positive HBs antigenemia with HBV DNA \> 1000 IU/ml((if positive AgHBs with HBV DNA ≤ 1000 IU/mL, patient will be included provided it is treated with Ténofovir) * Pregnant women, breast-feeding women * Refusal of adequate contraception * Contra-indication to Ribavirin, including hypersensitivity reaction to Ribavirin * Contra-indication to Peginterferon, including psychiatric contra-indications. Patients with significant psychiatric past history, notably severe depression requiring hospitalization or suicide attempt, cannot be included unless they undergo a psychiatric evaluation and obtain a specific authorization for the use of interferon. * Premature discontinuation (during the first six months) of a previous HCV treatment for toxicity. Patients who have stopped a previous treatment for severe anaemia or neutropenia can enter the study if erythropoietin or granulocyte growth factor had not been used during the previous treatment * Previous HCV therapy including HCV NS3 protease inhibitor * Severe pre-existing cardiac or pulmonary disease * History of organ transplant * Acute CDC stage C opportunistic infection occurring within the previouW6 months * Any active malignant disease including hepatocellular carcinoma for which a specific assessment is required at screening * Alcohol intake that may represent an obstacle for the participation of the subject in the study * Substance abuse that may represent an obstacle for the participation of the subject in the study. Stabilized patients included in a substitution program can participate in the study * Patients with previous observance problem unable to observe the study procedures * Participation in another clinical trial within the previous 30 days * Haemoglobin \< 90 g/L * Platelets \< 50 000 /mm3 * Neutrophil count \< 750 /mm3 * Renal insufficiency defined by an estimated Glomerular Filtration Rate \< 50 mL/mn (MDRD equation) * Absence of antiretroviral treatment or antiretroviral treatment different from the authorized combinations * Associated medication likely to interfere with any of the study drugs such as CPY3A4 inducers (rifampin, Millepertuis)